BRCA1 and ovarian carcinoma: Although PARPi is not yet considered as a radiosensitizer in patients with ovarian cancer harboring BRCA1/2 mutations in the clinic, the combination of radiotherapy with PARPi could provide promising synergistic therapeutic effects.